Abstract 100P
Background
Patients (pts) with persistent, recurrent, or metastatic cervical cancer are at high risk of progression after first-line standard treatment with platinum-doublet chemotherapy ± bevacizumab. Adding a PD-1 inhibitor to this standard treatment improves the survival of PD-L1+ pts. The preliminary results showed that tislelizumab plus bevacizumab and platinum-based chemotherapy had a promising efficacy with unconfirmed ORR of 78.4% (29/37, 95% CI, 61.8%-90.2%), irrespective of PD-L1 expression status (J Zhu, et al., JCO 2023 41:16_suppl). Here, we presented the updated results based on the full efficacy analysis set.
Methods
Eligible pts with persistent, recurrent, or metastatic cervical cancer received tislelizumab (200 mg, Q3W) plus bevacizumab (7.5 mg/kg, Q3W) and platinum-based chemotherapy. PD-L1 expression was accessed using VENTANA PD-L1(SP263) assay. The primary endpoint was PFS. Secondary endpoints were ORR, DCR, DOR and safety.
Results
A total of 50 pts were enrolled, with 46 (92.0%) having squamous cell carcinoma. 41 pts were detected for PD-L1 expression; 35 (85.4%) pts were PD-L1+, 6 (14.6%) were PD-L1–. As of 10 Aug 2023, the median follow-up was 7.8 months (range 0.8-14.6). Among 47 pts in the efficacy analysis set, the confirmed ORR was 72.3% (34/47, 95% CI 57.4%-84.4%), with CR rate of 14.9% (6/47). Subgroup analysis showed that ORR for pts with squamous cell carcinoma and adenocarcinoma were 72.7% (32/44) and 66.7% (2/3), respectively; ORR for pts with PD-L1+ and PD-L1– tumors were 70.6% (24/34) and 100% (5/5), respectively. DCR was 100% (95% CI 92.4%-100.0%). Median DOR and PFS were not reached. After a median treatment duration of 6.8 months, grade ≥3 treatment-related adverse events occurred in 48.0% of pts. Immune-related adverse events (irAE) were reported in 32.0% of pts, with no grade ≥3 irAE reported. Serious adverse events occurred in 20.0% of pts.
Conclusions
The updated results further demonstrated the efficacy and tolerability of tislelizumab plus bevacizumab and chemotherapy, with increased CR rate observed during extended treatment duration.
Clinical trial identification
NCT05247619.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
78P - Final Analysis of the French Real-World Study EVIDENS: Effectiveness, Safety & Quality of Life At 36 Months of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
Presenter: Fabrice Barlesi
Session: Poster Display
79P - A prospective, single-arm, phase II study to evaluate the efficacy and safety of Tislelizumab plus chemotherapy in resectable NSCLC
Presenter: Daqiang Sun
Session: Poster Display
80P - Efficacy and Safety of Tislelizumab Combined with Anlotinib and 2-cycles Chemotherapy as First-line Treatment for Advanced NSCLC(TISAL-FE-01)
Presenter: jun Tang
Session: Poster Display
81P - Real-World Experience with Docetaxel Regimens in Metastatic Non-Squamous (mNSq) Non-Small Cell Lung Cancer (NSCLC) Patients Previously Treated with Platinum-Based Chemotherapy (PCT) and an Immune Checkpoint Inhibitor (ICI) in the United States (US)
Presenter: Marisa Bittoni
Session: Poster Display
82P - The Role of Circadian Rhythms in NSCLC Immunotherapy Efficacy: A Focus on First Dose Timing
Presenter: Martin Igor Gomez-Randulfe Rodriguez
Session: Poster Display
84P - Adebrelimab plus chemotherapy (chemo) as first-line treatment for extensive-stage small-cell lung cancer (ES-SCLC): 3-year update of the phase 3 CAPSTONE-1 study
Presenter: Ying Cheng
Session: Poster Display
85P - Phase II trial of tislelizumab plus sitravatinib as maintenance therapy in extensive-stage small-cell lung cancer (ES-SCLC)
Presenter: Yun Fan
Session: Poster Display
86P - Durvalumab plus Olaparib as maintenance therapy in extensive-stage small-cell lung cancer (TRIDENT): updated efficacy and safety analysis
Presenter: Yan Huang
Session: Poster Display
88P - Adverse events (AEs) as potential predictive factors of activity in patients with advanced hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (AB)
Presenter: MARA PERSANO
Session: Poster Display